Research has been conducted on the safety and tolerability of using intranasal esketamine in conjunction with certain medications, specifically irreversible, nonselective monoamine oxidase inhibitors (MAOIs), for treatment-resistant depression. The findings are part of a broader exploration of ketamine and esketamine as treatment options for depression and other mental health conditions. The studies and reviews aim to synthesize existing evidence and provide guidance on practical applications for healthcare programs.